Semaglutide — Canada Research Brief
Semaglutide is a long-acting GLP-1 receptor agonist approved by Health Canada for type 2 diabetes (Ozempic, Rybelsus) and chronic weight management (Wegovy).
Key facts
| Canonical name | Semaglutide |
|---|---|
| Alternate names | Ozempic, Wegovy, Rybelsus, NN9535 |
| Drug class | GLP-1 receptor agonist |
| CAS number | 910463-68-2 |
| Molecular formula | C187H291N45O59 |
| Molecular weight | 4113.58 g/mol |
Mechanism
Semaglutide activates the GLP-1 receptor, a class B G-protein-coupled receptor expressed in pancreatic β-cells, gastric smooth muscle, and hypothalamic appetite circuits. Downstream effects include:
- Glucose-dependent insulin secretion from pancreatic β-cells, which improves postprandial glycaemia without the hypoglycaemia risk of sulfonylureas.
- Glucagon suppression from α-cells.
- Delayed gastric emptying, which flattens postprandial glucose peaks and contributes to early satiety.
- Central appetite suppression via GLP-1 receptor populations in the arcuate nucleus and area postrema.
The fatty-acid side chain on Lys26 binds reversibly to plasma albumin, which protects the peptide from DPP-4 cleavage and renal clearance and gives semaglutide its ~165-hour half-life — the basis for once-weekly dosing.
Clinical evidence
The most-cited dataset for semaglutide in weight management is the STEP programme — eight phase-3 trials published 2021–2023. STEP 1 (Wilding et al., NEJM 2021) reported a mean weight reduction of −14.9% at 68 weeks with once-weekly 2.4 mg subcutaneous dosing versus −2.4% for placebo, in adults with BMI ≥30 or ≥27 with comorbidity.
For cardiovascular safety, SUSTAIN-6 (Marso et al., NEJM 2016) demonstrated a 26% relative risk reduction in the primary MACE composite endpoint in adults with type 2 diabetes at elevated cardiovascular risk.
How Canadian researchers source semaglutide
Canadian labs sourcing research-grade semaglutide should verify three things on every vendor: (1) per-batch HPLC purity ≥98%, (2) mass spectrometry confirming the expected 4,113.58 g/mol mass, and (3) domestic Canadian shipping to avoid customs holds on international incretin peptide shipments.
Comparisons
- Semaglutide vs retatrutide — single- versus triple-agonist trade-offs.
- Semaglutide vs tirzepatide — GLP-1 alone versus GLP-1 / GIP dual.
Storage
Store lyophilised semaglutide at −20°C for long-term storage. Reconstituted peptide is stable refrigerated at 2–8°C for approximately 4 weeks. Avoid repeated freeze-thaw cycles. See our reconstitution guide for step-by-step handling.
Frequently asked questions
What is semaglutide?
Is semaglutide approved in Canada?
How does semaglutide differ from tirzepatide and retatrutide?
What is semaglutide's molecular weight?
References
- [1]Wilding JPH, Batterham RL, Calanna S, et al.. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine, 2021. DOI: 10.1056/NEJMoa2032183
- [2]Marso SP, Bain SC, Consoli A, et al.. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6). New England Journal of Medicine, 2016. DOI: 10.1056/NEJMoa1607141
- [3]National Center for Biotechnology Information. PubChem CID 56843331 — Semaglutide, 2024
Related research
- Retatrutide (LY-3437943) — Canada Research Briefpeptides
- MOTS-c — Canada Research Briefpeptides
- Tesamorelin — Canada Research Briefpeptides
- Tirzepatide — Canada Research Briefpeptides
- GLP-1 Peptides in Canada — Semaglutide, Tirzepatide, and Retatrutide Research Contextlearn
- Retatrutide vs Semaglutide — Canada Research Comparisoncompare